Systemic Lupus Erythematosus

1.    Binard A et al. Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus? J Autoimmun. 2008;30:63-7.
2.    Caligaris-Cappio F et al. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 1995;13:339-43.
3.    Crow MK et al. Regulation of CD40 ligand expression in systemic lupus erythematosus. Curr Opin Rheumatol 2001;13:361-9.
4.    Yazdany J et al. The role of CD40 ligand in systemic lupus erythematosus. Lupus 2004;13:377-80.
5.    Wong CK et al. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005;44:989-94.
6.    Crow MK. Interferon-alpha: a new target for therapy in systemic lupus erythematosus? Arthritis Rheum 2003;48:2396-401.
7.    Crow MK. Type I interferon in systemic lupus erythematosus. Curr Top Microbiol Immunol 2007;316:359-86.
8.    Xu Z et al. Determination of serum interleukin-13 and nerve growth factor in patients with systemic lupus erythematosus and clinical significance. J Huazhong Univ Sci Technolog Med Sci 2005;25:360-1.
9.    Tenbrock K et al. Transcriptional regulation of interleukin 2 in SLE T cells. Int Rev Immunol 2004;23:333-45.
10.    Wu T et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 2007;179:7166-75.
11.    Silvestris F et al. Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-1) in active lupus. Lupus 2003;12:8-14.
12.    Hao JH et al. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese. Arch Dermatol Res 2006;297:329-32
13.    Satoh A et al. Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 1999;26:1715-20.
14.    George-Chandy A et al. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008;10:R97.
15.    Koyama T et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:1065-7.
16.    Ramanujam M et al. BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled? Immunol Rev 2008;223:156-74.
17.    Wang XF et al. Changes of serum BAFF and IL-21 levels in patients with systemic lupus erythematosus and their clinical significance. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2007;23:1041-2.
18.    von Wussow P et al. Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol Int 1988;8:225-30.
19.    Katsumata Y et al. Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-alpha, IgG index, and Q-albumin. J Rheumatol 2007;34:2010-7.
20.    Chun HY et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007;27:461-6.
21.    Wang H et al. The abnormal apoptosis of T cell subsets and possible involvement of IL-10 in systemic lupus erythematosus. Cell Immunol 2005;235:117-21.
22.    Wong CK et al. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000;9:589-93.
23.    Tsai CY et al. Decreased IL-12 production by polymorphonuclear leukocytes in patients with active systemic lupus erythematosus. Immunol Invest 2002;31:177-89.
24.    Crispín JC et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008;181:8761-6.
25.    Amerio P et al. Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin Exp Rheumatol 2002;20:535-8.
26.    Sabry A et al. Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine 2006;35:148-53.
27.    Hammad AM et al. Transforming growth factor beta 1 in children with systemic lupus erythematosus: a possible relation with clinical presentation of lupus nephritis. Lupus 2006;15:608-12.
28.    Heilig B et al. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease. J Clin Immunol 1993;13:321-8.